



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Actemra® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)	Provider Information (required)
-------------------------------	---------------------------------

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Active polyarticular juvenile idiopathic arthritis (PJIA)

Active systemic juvenile idiopathic arthritis (SJIA)

Cytokine release syndrome (CRS)

Giant cell arteritis

Moderately to severely active rheumatoid arthritis (RA)

Other diagnosis: _____ ICD-10 Code(s): _____

Prescriber's Specialty:

Select if Actemra is prescribed by or in consultation with one of the following specialists, as appropriate for the patient's diagnosis:

Hematologist

Oncologist Corlanor_FSVF_2019Jan

Rheumatologist

For active polyarticular juvenile idiopathic arthritis (PJIA), answer the following:

Select if the patient has had trial and failure, contraindication, or intolerance to the following non-biologic disease modifying anti-rheumatic drugs (DMARDs):

Arava (leflunomide)

Rheumatrex/Trexall (methotrexate)

Has the patient had trial and failure, contraindication, or intolerance to Humira (adalimumab)? Yes No

For active systemic juvenile idiopathic arthritis (SJIA), answer the following:

Has the patient had trial and failure, contraindication, or intolerance to one non-steroidal anti-inflammatory drug (NSAID) (e.g., Motrin [ibuprofen], Naprosyn [naproxen])? Yes No

Has the patient had trial and failure, contraindication, or intolerance to systemic glucocorticoid (e.g., prednisone)? Yes No

For cytokine release syndrome, answer the following:

Will the patient receive or is receiving chimeric antigen receptor (CAR) T-cell immunotherapy [i.e., Kymriah (tisagenlecleucel) Yescarta (axicabtagene ciloleucel)]? Yes No

For giant cell arteritis, answer the following:

Has the patient had trial and failure, contraindication, or intolerance to glucocorticoid (i.e., prednisone)? Yes No

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
Office use only: Actemra_Comm_2019Jan-W



Actemra® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For moderately to severely active rheumatoid arthritis (RA), answer the following:

Has the patient had trial and failure, contraindication, or intolerance to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Rheumatrex/Trexall (methotrexate), Arava (leflunomide), Azulfidine (sulfasalazine)]? Yes No

Select if the patient has history of failure, contraindication, or intolerance to the following, or attestation demonstrating a trial may be inappropriate:

- Cimzia (certolizumab)
- Humira (adalimumab)
- Simponi (golimumab) or Simponi Aria (golimumab IV)

Select if the patient has history of failure, contraindication, or intolerance to the following:

- Kevzara (sarilumab)
- Xeljanz (tofacitinib) or Xeljanz XR (tofacitinib ER)

Is this request for continuation of prior Actemra therapy? Yes No

Reauthorization:

For active polyarticular juvenile idiopathic arthritis (PJIA), active systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis, or moderately to severely active rheumatoid arthritis (RA) requests, answer the following questions:

Is there documentation the patient has had a positive clinical response to Actemra therapy? Yes No

Quantity Limit Requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.